Merck Serono Drops Diabetes Investment After Portfolio Review
This article was originally published in The Pink Sheet Daily
German biopharma seeks licensing partners for diabetes treatments now in development while firm focuses R&D on cancer, other indications.
You may also be interested in...
Company and partner Merck Serono also are working with FDA to finalize protocol for study in general systemic lupus erythematosus.
Merck will pursue lower dose in future clinical trials, firm tells “The Pink Sheet” DAILY.
Merck acquires family-owned shares representing 64.5% of Serono's capital and will launch a tender offer for the remainder, at a total value of $13.27 bil.